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ABSTRACT 25 
Utilizing BRAFV600E  mutation as a marker may reduce unnecessary prophylactic central neck 26 
dissection (pCND) in clinically-nodal negative (cN0) neck for small (≤2cm) classical papillary 27 
thyroid carcinoma (PTC). We aimed to assess whether BRAF is a significant independent 28 
predictor of occult central nodal metastasis (CNM) and its contribution to the overall prediction 29 
after adjusting for other significant preoperative clinical factors in small PTC. Primary tumor 30 
tissue (paraffin-embedded) from 845 patients with small classical cN0 PTC who underwent 31 
pCND was tested for BRAF mutation. Clinicopathologic factors were compared between those 32 
with and without BRAF. BRAF was evaluated to see if it was an independent factor for CNM. 33 
Prediction scores were generated using logistic regression models and their predictability was 34 
measured by the area under the ROC curve (AUC). The prevalence of BRAF was 628/845 35 
(74.3%) while the rate of CNM was 285/845 (33.7%). Male sex (OR=2.68,95%CI=1.71-4.20), 36 
large tumor size (OR=2.68,95%CI=1.80-4.00), multifocality (OR=1.49,95%CI=1.07-2.09), 37 
lymphovascular permeation (OR=10.40,95%CI=5.18-20.88) and BRAF (OR=1.65,95%CI=1.10-38 
2.46) were significant independent predictors of CNM while coexisting Hashimoto’s thyroiditis 39 
(OR=0.56,95%CI=0.40-0.80) was an independent protective factor. The AUC for prediction 40 
score based on tumor size and male sex was similar to that of  prediction score based on tumor 41 
size, male sex and BRAF status (0.68 vs. 0.69,p=0.60). Although BRAF was an independent 42 
predictor of CNM, knowing its status did not substantially improve the overall prediction. A 43 
simpler prediction score based on male sex and tumor size might be sufficient.44 
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INTRODUCTION 45 
Papillary thyroid carcinoma (PTC) is the most common type of differentiated thyroid carcinoma 46 
with an adjusted incidence doubled over the last 20 years (Kilfoy et al., SEER 2013, HKCR 47 
2013). Despite its relatively good prognosis, locoregional recurrence (LR) is common (Wong et 48 
al. 2012). With recognition of the concept of step-wise progression of lymph node metastasis 49 
originating from the central (level VI) to the lateral compartment (levels II-V) and the fact that 50 
preoperative ultrasonography (USG) only identifies approximately half of the central nodal 51 
metastasis (CNM), a growing number of surgeons have advocated routine prophylactic central 52 
neck dissection (pCND) at the time of the total thyroidectomy (TT) (Machens et al. 2009, 53 
Hwang et al. 2011, Roh et al. 2009). However, this remains controversial particularly in low-risk 54 
PTC as the American Thyroid Association (ATA) only recommends central neck dissection 55 
(CND) in clinically involved (cN1) neck lymph nodes or in T3 and T4 tumors (Cooper et al. 56 
2009). Although a recent meta-analysis has found that those with cN0 neck who undergo pCND 57 
might have reduced risk of LR than those who undergo TT-alone in the short-term, the former 58 
group has higher risks for temporary hypoparathyroidism and overall morbidity (Lang et al. 59 
2013a). Therefore, identification of predictive factors for occult CNM is crucial to reduce 60 
unnecessary pCND (Koo et al. 2009, Hartl et al. 2012, Zhao et al. 2013, Zhang et al. 2012). 61 
In recent years, a T1799A point mutation in the v-raf murine sarcoma viral oncogene homolog 62 
B1 (BRAF) resulting in a valine-to-glutamic acid switch at codon 600 (BRAFV600E) has emerged 63 
as a molecular marker for aggressive behavior in PTC (Xing et al. 2005, Xing et al. 2013a). 64 
Previous studies have found that BRAF+ve tumors are significantly larger in size, more frequent 65 
lymph node metastasis and extrathyroidal extension and also higher tumor stage, risk of LR and 66 
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disease-related mortality than BRAF-ve tumors (Li et al. 2012, Alzahrani & Xing. 2013, Frasca 67 
et al. 2008, Xing et al. 2009, Xing et al. 2013b, O’Neill et al. 2010, Kim et al. 2012). Therefore, 68 
in addition to the existing prognostic staging systems,(Lang et al. 2007a) BRAF mutation could 69 
be used as a potential marker for stratifying tumor risk (Xing et al. 2009, Yip et al. 2009, Howell 70 
et al. 2013). Previous studies have examined the utility of BRAF mutation testing in optimizing 71 
surgical management and suggested that BRAF+ve patients may benefit from more extensive 72 
initial surgery such as pCND (Xing et al. 2009, O’Neill et al. 2010, Yip et al. 2009, Joo et al. 73 
2012). Joo et al. evaluated the utility of BRAF mutation by pyrosequencing on 148 preoperative 74 
fine needle aspiration (FNA) specimens and concluded that preoperative BRAF analysis by FNA 75 
could help to predict occult CNM (Joo et al. 2012). However, most studies only evaluated the 76 
association of BRAF with overall presence of lymph node metastasis rather than occult CNM 77 
alone (Frasca et al. 2008, Xing et al. 2009, O’Neill et al. 2010, Kim et al, 2012, Yip et al. 2009, 78 
So et al. 2011, Kim et al. 2006, Nam et al. 2012). In addition, there have been few studies 79 
adopting the strict definition of a pCND when examining the association between BRAF 80 
mutation and lymph node metastasis (Howell et al. 2013, Paulson et al. 2012, Lee et al. 2-12, 81 
Dutemhefner et al 2013). Furthermore, in some studies (Xing et al. 2005, Frasca et al. 2008, So 82 
et al. 2011, Kim et al. 2006, Nam et al. 2012), after adjusting for other significant 83 
clinicopathologic factors such as age, sex, multifocality, tumor size and extrathyroidal extension, 84 
BRAF became non-significant. Therefore, currently there is still insufficient data to support 85 
pCND on the basis of BRAF mutation status alone in low-risk PTC (Xing et al. 2013a). Given 86 
these controversies, our study aimed to assess whether BRAF mutation was a significant 87 
independent predictor of occult CNM in cN0 neck and also the role of BRAF mutation in 88 
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contributing to the overall prediction after adjusting for other significant preoperative clinical 89 
factors in a large cohort of small (≤2cm) PTC. 90 
91 
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PATIENTS AND METHODS 92 
Patients 93 
The present study protocol was approved by the local institutional review board (IRB No:H-94 
1305-020-486). All consecutive patients who underwent total thyroidectomy and CND at Seoul 95 
National University Hospital from December 2008 – November 2012 were retrospectively 96 
analyzed. All data were collected prospectively. Patients who were diagnosed preoperatively by 97 
FNA or intraoperatively on frozen section were included. Figure 1 shows the study flow chart. 98 
Altogether there were 1916 patients with small (≤2cm) classic PTC who underwent total 99 
thyroidectomy and CND. All tumors classified as histological variants of PTC (including 100 
follicular variant) (n=52) (see Table 1) or with pathologic size >2.0cm were excluded. Of the 101 
1916 patients, 168 (8.8%) were excluded because BRAF testing was not done or available while 102 
457 (23.9%) were excluded because they were suspicious of or cytologically-confirmed to have 103 
lymph node metastases detected on preoperative neck USG or intraoperative evaluation. Within 104 
this latter group, 363 patients subsequently underwent lateral selective neck dissection while the 105 
other 94 underwent therapeutic CND. Therefore, there were 1291 clinically nodal negative PTC 106 
patients who underwent TT + prophylactic CND (pCND) and had their tumor tissue tested for 107 
BRAF mutation. To ensure an adequate pCND specimen, those patients with less than 3 central 108 
lymph nodes (CLNs) harvested by pCND were excluded (n=446). Therefore, 845 patients were 109 
eligible for analysis. However, since a substantial proportion of patients were excluded, 110 
patient/tumor characteristics were compared between the two groups to look for possible 111 
selection bias on the basis of CLN yield. 112 
Methods 113 
DNA isolation from surgical specimen and FNA samples  114 
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B-type Raf Kinase V600E (BRAFV600E) mutation analysis from surgical specimen was conducted 115 
prospectively and routinely for all patients with PTC after February 2009.  From the surgical 116 
specimen, areas of tumor were identified on hematoxylin and eosin (H&E) stained slides, 117 
marked by pathologists and dissected using a fine needle from 10-μm-thick unstained sections. 118 
In patients with bilateral or multifocal tumors, only the largest focus was examined for the 119 
BRAFV600E mutation. Genomic DNA was isolated by incubation with extraction buffer [1 M Tris-120 
HCl, pH 7.4; 0.5 Methylenediaminetetraacetic acid (EDTA), pH 8.0, 5% Tween 20] and 121 
proteinase K at 60°C for 12–15 h, followed by standard phenol-chloroform extraction and 122 
ethanol precipitation.  123 
To see correlation of BRAF between surgical specimen and FNA sample, the results of BRAF 124 
test from the two materials were compared in 19 patients who had BRAF mutation analysis from 125 
FNA samples before surgery. All FNAs were carried out under ultrasound guidance. All 126 
aspirations (usually 2 passes for each lesion) were obtained with 25-gauge or 27-gauge needles. 127 
The aspirated material was fixed with a hemolytic and preservative solution (Cytolit; Hologic 128 
Cytyc Company) after rinsing the needle into this solution. The resulting slide was fixed in 95% 129 
ethanol and stained with Papanicolaou. DNA extraction was performed on FNA samples using 130 
the ThinPrep 2000 system (Hologic Cytyc Company) using the QIAamp tissue kit (Qiagen, 131 
Hilden, Germany). 132 
BRAFV600E mutation analysis 133 
The BRAF exon 15, which contains the most common BRAF mutation, a T1799A transversion 134 
(BRAFV600E), was amplified by polymerase chain reaction (PCR) with genomic DNA. The 135 
primers and PCR conditions were as follows: forward, 5'-136 
TCATAATGCTTGCTCTGATAGGA-3'; reverse 5'-GGCCAAAAATTTAATCAGTGGA-137 
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3'; denaturation at 94°C for 10 min, followed by 35 cycles of 94°C for 1 min, 60°C for 1 min, 138 
72°C for 1 min, and a final extension step at 72°C for 10 min. After purification of the PCR 139 
products with the QIAGEN-QIAquick PCR purification kit (QIAGEN, Hilden, Germany), direct 140 
DNA bidirectional sequencing was done with an ABI 3130XL Genetic Analyzer BigDye 141 
Terminator (Applied Biosystems, Foster City, CA). Sequence data were analyzed manually by 142 
two independent pathologists 143 
Management of PTC 144 
A preoperative USG was routinely performed to examine both central and lateral neck 145 
compartments with any suspicious nodes aspirated for cytology. TT was the preferred procedure 146 
for all patients with a preoperative diagnosis of PTC. Once the diagnosis of PTC had been 147 
confirmed by frozen section, regardless of the tumor size or local extent, an ipsilateral pCND 148 
was performed for unifocal tumors while a bilateral pCND was performed for bilateral or isthmic 149 
tumors. All pCND were carried out in accordance to anatomical landmarks described by the 150 
ATA (Carty et al. 2009) and were performed immediately after the completion of the TT. It 151 
comprised the removal of all nodes and fibro-fatty tissue extending vertically from the hyoid 152 
bone to the thoracic inlet and laterally from the medial border of common carotid artery to the 153 
midline of the trachea. The ipsilateral recurrent laryngeal nerve (RLN) was mobilized and 154 
skeletonized along its entire cervical course. 155 
Postoperative assessment 156 
All post-surgical patients were followed up within 1-2 weeks and then 2-3 monthly for the first 157 
year. Those taking calcium +/- calcitriol supplements were followed more frequently with an aim 158 
of gradually weaning off these supplements while maintaining normocalcemia. By definition, 159 
those who discontinued all supplements in the presence of normocalcemia ≤ 6 months after 160 
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surgery were regarded as temporary hypoparathyroidism whereas those who continued for >6 161 
months were categorized as permanent hypoparathyroidism. Also both vocal cords were 162 
examined endoscopically 1-2 days before and within 2 weeks after thyroidectomy using flexible 163 
laryngoscope. Any reduction in cord movement was recorded as vocal cord palsy. Those with 164 
vocal cord palsy were examined every 3 months. The presence of cord palsy lasting > 6 months 165 
was regarded as permanent. 166 
Follow-up protocol 167 
All post-surgical patients were followed up within 2 weeks in a specialized oncology clinic. A 168 
follow-up visit was conducted at 3-month, 6-month and then annually thereafter. Clinical 169 
examination, neck USG and non-stimulated Tg level were done during follow-up visits. 170 
Stimulated thyroglobulin (sTg) was defined as a Tg level measured in the presence of TSH >30 171 
mIU/L either by thyroxine withdrawal or recombinant TSH injections. Radioiodine (RAI) 172 
ablation and pre-ablation sTg level were done approximately 3 months after surgery (because 173 
most patients would have had a contrast CT before they were referred to us for neck USG and 174 
surgery) while the post-ablation sTg level was taken approximately 9 months after surgery (6-7 175 
months after RAI ablation). Tg autoantibodies were measured at the same time. The decision for 176 
RAI was based on presence of ≥1 risk factors such as tumor size >1.5cm, lymph node metastasis, 177 
age >45 years old, extrathyroidal extension, macroscopic postoperative residual disease in the 178 
neck and distant metastasis.  Thirty millicuries (mCi) I131 was the standard ablative dose for 179 
low-risk PTC. TSH suppression to <0.1 mIU/L was recommended for high- and intermediate-180 
risk patients. All relevant clinical, laboratory, radiologic, and perioperative data were collected 181 
prospectively and follow-up data were regularly updated in a computerized database. 182 
Statistical analysis 183 
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Continuous variables were expressed as mean±SD and groups were compared using the Mann-184 
Whitney U test. Chi-square tests were used to compare categorical variables. Any 185 
clinicopathologic features which were statistically significantly associated with occult CNM in 186 
the univariate analysis were entered into multivariate analysis by logistic regression to determine 187 
independent factors and to formulate combined prediction scores based on the regression 188 
coefficients. The area under a receiver characteristic (ROC) curve (AUC) was used to measure 189 
the relative predictability of independent factors and combined prediction scores. AUC values 190 
close to 1.00 meant better predictability whereas close to 0.500 meant poorer predictability. A 191 
bootstrap approach with 1,000 resamples was used to compare AUCs and to estimate 95% 192 
confidence intervals for each AUC. All statistical analyses were conducted using SPSS version 193 
18.0 (SPSS, Inc., Chicago, IL, USA) and R version 2.14.0 (R Foundation for Statistical 194 
Computing, Vienna, Austria). P values below 0.05 were considered statistically significant.195 
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RESULTS 196 
Our cohort was mostly females (86.7%). The mean (±SD) and median (range) age at operation 197 
were 45.7 ± 11.9 and 46.0 (12.0 – 77.0) years old, respectively. The mean (±SD) tumor size was 198 
0.8 ± 0.4cm. The mean (±SD) number of CLNs and positives CLNs removed were 6.6 ± 3.8 and 199 
0.9 ± 1.8, respectively. The overall rate of occult CNM was 285/845 (33.7%) while the rate of 200 
BRAF+ve mutation in primary tumors was 628/845 (74.3%).  201 
Table 2 shows a comparison of patient characteristics between those with ≥3 CLNs and with <3 202 
CLNs. There were no significant differences except for a higher concomitant Hashimoto’s 203 
thyroiditis (HT) (p<0.001) and CNM (p<0.001) for those with ≥3 CLNs. 204 
Table 3 shows a comparison of patient clinicopathological features, tumor characteristics and 205 
TNM tumor stages between BRAF+ve and BRAF–ve groups. Age and sex ratio were similar 206 
between the two groups. The BRAF+ve group had significantly larger sized tumors (0.8cm vs. 207 
0.7cm, p<0.001) and higher incidence of extrathyroidal extension (61.0% vs. 43.3%, p<0.001) 208 
and occult CNM (37.4% vs. 23.0%, p<0.001) while the incidence of coexisting HT was 209 
significantly less (34.6% vs. 52.5%, p<0.001) than the BRAF-ve group. The number of CLNs 210 
harvested was similar between the two groups regardless of the extent of pCND but the overall 211 
number of metastatic CLNs excised and the central lymph node ratio (CLNR) in the BRAF+ve 212 
group were significantly higher than in the BRAF-ve group (1.0 vs. 0.7, p<0.001 and 16.1% vs. 213 
10.6%, p<0.001). However, when stratified into unilateral and bilateral pCND, these significant 214 
differences were not observed with bilateral pCND. The BRAF+ve group had significantly 215 
higher proportion of stage III tumors and a corresponding lower proportion of stage I tumors 216 
than BRAF-ve group. As a result, RAI ablation was given more frequently in the BRAF+ve group 217 
(35.2% vs. 22.6%, p=0.001). After excluding those with elevated anti-Tg antibody, the pre-218 
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ablation sTg level in the BRAF+ve group was significantly higher than the BRAF-ve group 219 
(2.4ug/L vs. 1.0ug/L, p=0.032) while the post-ablation sTg was similar (0.6ug/L vs. 0.2ug/L, 220 
p=0.473). 221 
Table 4 shows a comparison of patient clinicopathologic features, tumor characteristics and 222 
BRAF mutation status between those with (N1a group) and those without occult CNM (N0 223 
group). Age was similar between the two groups but the proportion of males was significantly 224 
higher in the N1a group (22.5% vs. 8.6%, p=0.023). Also N1a group had significantly larger 225 
sized tumors (0.8cm vs. 0.7cm, p=0.001) and higher incidence of tumor multifocality (41.4% vs. 226 
31.1%, p=0.003), extrathyroidal extension (69.1% vs. 50.0%, p<0.001), lymphovascular 227 
permeation (20.4% vs. 2.1%, p<0.001) and BRAF+ve mutation status (82.5% vs. 70.2%, 228 
p<0.001). However, N1A group had significantly lower incidence of coexisting HT than N0 229 
group (26.7% vs. 45.5%, p<0.001) 230 
Table 5 shows the multivariate analysis for occult CNM. Male sex (OR=2.681, 95%CI=1.709  231 
4.202, p<0.001), large tumor size (OR=2.684, 95%CI=1.802 – 3.997, p<0.001), tumor 232 
multifocality (OR=1.491, 95%CI=1.065 – 2.087, p=0.020), lymphovascular permeation 233 
(OR=10.395, 95%CI=5.176 – 20.877), p<0.001), and BRAF+ve mutation (OR=1.647, 234 
95%CI=1.101 – 2.463, p=0.015) were independent risk factors while coexisting HT (OR=0.560, 235 
95%CI=0.396 – 0.792, p=0.001) was an independent protective factor for occult CNM. 236 
Since only male sex, tumor size and BRAF+ve mutation are potentially known before operation 237 
(i.e without histopathology), these 3 factors were used to formulate a preoperative prediction 238 
score by logistic regression. Table 6a shows a comparison of predictability as measured by area 239 
under the receiver operating characteristic curve (AUC) between tumor size and two combined 240 
prediction scores. Although the AUC of the three prediction scores were not significantly 241 
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different, the most important was that the AUC for prediction score 3 (based on tumor size, male 242 
sex and BRAF) was not significantly higher than that of prediction score 2 (based on tumor size 243 
and male sex) (0.69 vs. 0.68, p=0.60). Therefore, despite being an independent predictor in the 244 
multivariate analysis (see Table 5), knowing the BRAF mutation status did not add substantially 245 
to the overall prediction of occult CNM. Table 6b shows a comparison of occult CNM rate 246 
between each quartile of prediction score 2 and 3. For both scores, the chance of occult CNM 247 
increased from <20% to 55% as the prediction score increased from the first to the fourth quartile. 248 
Table 7 shows the correlation of BRAF mutation status between FNA and surgical specimen. Of 249 
the 19 patients, 17 had matched BRAF results while 2 had mismatched results. For these 2 250 
mismatched cases, both were BRAF+ve on FNA but BRAF-ve on surgical specimen.  The 251 
correlation rate between FNA and surgical specimen was 89.5%. 252 
Table 8a shows a 2x2 table between BRAF mutation and CNM. The sensitivity and specificity of 253 
BRAF+ve mutation status in predicting occult CNM were 235/285 (82.5%) and 167/560 (29.8%), 254 
respectively while the positive (PPV) and negative predictive values (NPV) were 235/628 255 
(37.4%) and 167/217 (77.0%), respectively. To simulate what might happen with lower BRAF 256 
prevalences, Table 8b shows a 2x2 table between BRAF positivity and CNM when the BRAF 257 
prevalence was lowered to 40%. The sensitivity, specificity, PPV and NPV became 51.9%, 258 
64.8%, 37.3% and 76.9%, respectively. 259 
In terms of clinical outcomes, rate of temporary and permanent hypocalcemia were 32.7% and 260 
1.9%, respectively while temporary and permanent RLN injury were 8.9% and 1.4%. After a 261 
mean follow-up of 9.4 ± 5.4 months, there was no LR detected. 262 
263 
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DISCUSSION 264 
The optimal initial surgical management for PTC patients without preoperative or intraoperative 265 
evidence of nodal involvement (i.e. cN0 PTC) remains controversial as the ATA currently only 266 
recommends CND for those with cN1 PTC. However, since pCND may reduce LR in the short-267 
term (Lang et al, 2013a), a more selective approach to minimize overall surgical morbidity 268 
would seem sensible and perhaps, cost-saving in the long-term (Lang et al. 2013a, Lang & Wong 269 
2013b). It is worth noting that despite our cohort comprised of patients with no evidence of 270 
clinical or ultrasound evidence of CNM, the presence of occult CNM was still 33.7%. This 271 
finding is of interest because of the recent discussions on whether pCND is justified and on 272 
whether RAI should be given more selectively (Cooper et al. 2009). In terms of surgical 273 
morbidity, our rates of hypocalcemia and RLN injury after pCND was not significantly higher or 274 
different from our previous series without pCND performed (Chung et al. 2007) and were 275 
comparable to the literature (Lang et al. 2013a). 276 
To our knowledge, this is one of the largest studies examining the association between BRAF 277 
mutation and occult CNM in cN0 PTC. To ensure that BRAF was truly a preoperative rather than 278 
a postoperative predictor, a small proof of principle series of 19 FNA cases was conducted and 279 
showed an 89.5% correlation of BRAF between FNA samples and surgical specimens. Similar to 280 
previous studies (Li et al. 2012, Frasca et al. 2008, Xing et al. 2009), our data confirmed that the 281 
BRAF+ve group had significantly larger, more advanced and aggressive tumors than the BRAF-282 
ve group. It was interesting to find that the BRAF+ve group had significantly less coexisting HT 283 
on histology (34.6% vs. 52.5%, p<0.001). This finding appeared to concur to previous studies 284 
which found reduced peritumoral lymphocytic infiltration in BRAF+ve PTCs (Virk et al. 2013, 285 
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Sargent et al. 2006). Although the precise reason for this remains unclear, a recent study 286 
demonstrated that tumors with coexisting HT behaved less aggressively and had a better 287 
prognosis than those without coexisting HT (Dvorkin et al. 2013). Therefore, this inverse 288 
association was in keeping with the concept that BRAF+ve tumor behaved more aggressively. 289 
Our data also showed that the pre-ablation sTg level was significantly higher in BRAF+ve group 290 
implying that the risk of microscopic residual disease after a total thyroidectomy with pCND 291 
might still have been higher in the BRAF+ve group. Nevertheless, the post-ablation sTg was 292 
similar and so, a longer follow-up was necessary to evaluate its true impact of BRAF on survival 293 
outcomes. However, unlike other studies, our study did not find significant association between 294 
age, sex, tumor bilaterality and multifocality with BRAF mutation (Li et al. 2012, Kim et al 2006, 295 
Nam et al 2012). 296 
In terms of predicting occult CNM, male sex, tumor size, tumor multifocality, lymphovascular 297 
permeation, coexisting HT and BRAF mutation were independent risk factors by multivariate 298 
analysis. Although two large previous studies also reported similar findings, neither examined 299 
the role of BRAF in the context of other significant clinicopathological factors (So et al. 2011, 300 
Zhang et al. 2012). Paulson et al. reported their experience of 175 classic cN0 PTC but found no 301 
association between BRAF mutation and occult CNM (Paulson et al. 2012). Two similarly-302 
designed but smaller studies also did not find any significant association between BRAF 303 
mutation and occult CNM (Lee et al. 2012, Dutenhefner et al. 2013). In fact, in one of the 304 
studies, the authors went further and concluded that it was premature in utilizing BRAF mutation 305 
status to decide whether or not to perform pCND in cN0 PTC (Lee et al. 2012). In contrast to 306 
these previous studies, although we did find that BRAF mutation status (OR=1.65, 307 
95%CI=1.101 – 2.463) was an independent predictor of occult CNM in cN0 PTC, it did not 308 
17 
 
contribute significantly to the overall prediction. When formulating preoperative prediction 309 
scores using male sex, tumor size and BRAF+ve mutation, although the predictability (as 310 
measured by AUC) improved with each additional factor entered into the prediction score (i.e. 311 
from prediction score 1 to 3), the improvement in predicting occult CNM was not statistically 312 
significant. Our data found that using a simpler prediction score of tumor size and male sex alone, 313 
the prediction (as measured AUC) was similar to a more complicated prediction score of tumor 314 
size, male sex and BRAF mutation (0.68 vs. 0.69, p=0.60). Given the fact that BRAF testing is 315 
associated with extra cost, perhaps a simpler prediction score based on male and tumor size 316 
might be sufficient. Therefore, although BRAF mutation was an independent predictor for occult 317 
CNM, it did not substantially or significantly improve the overall prediction of occult CNM in 318 
cN0 patients. Despite the high pre-test probability (74.3%) of BRAF positivity, both the 319 
specificity (29.8%) and PPV (37.4%) were relatively low and so these further emphasized the 320 
fact that BRAF mutation was not useful in predicting CNM in small cN0 PTC.  321 
However, it is worth noting that based on the adjusted OR, the BRAF+ve tumor in our study only 322 
had a 1.6 – 1.7 times greater chance of harboring occult CNM than a BRAF-ve tumor whereas to 323 
date, two other studies which found significant association had almost twice as high adjusted OR 324 
values (Howell et al 2013, Joo et al. 2012). Perhaps, in these studies, BRAF mutation might have 325 
a more significant impact on the overall prediction. Also we would like to acknowledge several 326 
shortcomings. Firstly, this was a retrospective analysis and so was prone to selection biases. 327 
Secondly, although our series of 19 FNA cases did show a 89.5% correlation between FNA 328 
samples and surgical specimens, our study was principally based on paraffin-embedded sections 329 
after thyroidectomy and so our results might be slightly different from studies which tested 330 
BRAF mutation primarily from FNA samples. Therefore, our study could not be strictly 331 
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considered to be examining the association between preoperative BRAF mutation and occult 332 
CNM. Nevertheless, even assuming that our study was entirely based on FNA samples, our 333 
conclusion would not have changed because this would have further lowered the predictability of 334 
BRAF mutation due to the lower detection BRAF on FNA samples (Yip et al. 2009). Thirdly, due 335 
to the strict definition of pCND, over a third of patients with inadequate number of CLNs had to 336 
be excluded from analysis. Although by excluding such substantial number of patients may 337 
introduce selection bias, the comparison of patient/tumor characteristics between those with 338 
≥3CLNs (n=845) and with <3CLNs (n=446) did not reveal significant differences (Table 2). The 339 
only differences were those with ≥3 CLNs had significantly higher percentages of coexisting HT 340 
and CNM than those with <3 CLNs. The former finding could be explained by the fact that HT 341 
tended to have larger-sized CLNs and that led to higher CLN yield (Hartl et al. 2012) while the 342 
latter finding was probably due to inadequate nodes sampled and nodal under-staging (Lang et al. 343 
2007b, Lang et al. 2012). Lastly, we would like to highlight the fact that our overall prevalence 344 
of BRAF positivity was relatively high (74.3%) when compared to that of other studies when 345 
only classical PTC were considered (≈45%) (Lee et al. 2012, Xing et al. 2013b). This is 346 
particularly interesting given the fact that these patients had small cN0 PTC. Although by 347 
including only the classical subtype of PTC did increase the overall prevalence of BRAF 348 
positivity from 72.9% to 74.3%, this increase was small because these variants only accounted 349 
for 5.8% of the entire cohort (see Table 1). Therefore, the exact reason for such high prevalence 350 
of BRAF positivity in our cohort remains unclear and may be due to geographical, genetic or 351 
diet-linked factors, as suggested previously (Frasca et al. 2008). However, it is worth noting that 352 
in our locality, the prevalence of BRAF positivity has been reported to be much higher (60-70%) 353 
than other parts of the world (Chung et al. 2006, So et al. 2011) and so this was unlikely due to a 354 
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selection or institutional bias. When the prevalence of BRAF mutation was lowered, our data 355 
showed that only the sensitivity and specificity of BRAF reversed while PPV and NPV remained 356 
static (see Table 8A and 8B). Although the absolute risk predicted by our model (Table 6b) may 357 
differ slightly with lower BRAF mutation prevalence, we think that the increased risk of occult 358 
CNM associated with BRAF should be generalizable. However, we would acknowledge the 359 
applicability of BRAF mutation as a marker to reduce unnecessary pCND could be weakened due 360 
to the high prevalence of BRAF positivity in our cohort. Nevertheless, this was one of the largest 361 
studies aimed at examining the association between BRAF mutation and occult CNM in small 362 
cN0 PTC. 363 
Conclusion 364 
Among the cN0 PTC patients who underwent pCND, the BRAF+ve tumors were significantly 365 
larger in size, had more extrathyroidal extension, occult CNM, higher CLNR, pre-ablation sTg 366 
level but less coexisting HT than the BRAF-ve tumors. Male sex, large tumor size, tumor 367 
multifocality, LV permeation and BRAF mutation were significant independent predictors of 368 
occult CNM while coexisting HT was a significant independent protective factor. When BRAF 369 
mutation was entered into logistic regression to formulate a prediction score, that score was not 370 
significantly better than that of a prediction score based on male and tumor size only. Therefore, 371 
based on our analysis using primarily paraffin-embedded tissue, despite being an independent 372 
predictor of CNM, BRAF did not add substantially to the overall prediction of occult CNM. 373 
Given the extra cost associated with BRAF testing, a simpler prediction score based on male and 374 
tumor size might be sufficient. 375 
376 
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FIGURE LEGEND 519 
Figure 1. The study flowchart520 
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Table 1. Prevalence of BRAF mutation in the classic papillary thyroid carcinoma (n=845) and the 521 
excluded histopathologic variants (n=52) 522 
Variant of papillary thyroid carcinoma BRAF mutation (%) 
- Classic / conventional (n=845) 628 (74.3) 
- Follicular variant (n=21) 7 (33.3) 
- Tall cell (n=15) 14 (93.3) 
- Oncocytic (n=11) 4 (36.4) 
- Diffuse sclerosing (n=2) 1 (50.0) 
- Solid cell (n=2) 0 (0.0) 
- Clear cell (n=1) 0 (0.0) 
 523 
524 
30 
 
Table 2. A comparison of patient/tumor characteristics between those with ≥3 central lymph 525 
nodes (CLNs) harvested and those with <3CLNs harvested during prophylactic central neck 526 
dissection 527 
 Patients with ≥3CLNs  
harvested (n=845) 
Patients with <3CLNs 
harvested (n=446) 
p-value 
Age at operation (years) 45.7 ± 11.9 46.5 ± 11.7 0.218 
Sex 
- Male 
- Female 
 
112 (13.3) 
733 (86.7) 
 
76 (17.0) 
370 (83.0) 
0.116 
Tumor characteristics 
- Tumor size (cm) 
- Tumor bilaterality 
- Tumor multifocality 
- Extra-thyroidal extension 
- LV permeation 
- Coexisting HT 
- Occult CNM (pN1a) 
 
0.8 ± 0.4 
171 (20.2) 
292 (34.6) 
477 (56.4) 
70 (8.3) 
331 (39.2) 
285 (33.7) 
 
0.8 ± 0.4 
73 (16.4) 
133 (29.8) 
254 (57.0) 
30 (6.7) 
60 (13.5) 
66 (21.4)* 
 
0.546 
0.087 
0.085 
0.828 
0.780 
<0.001 
<0.001 
BRAF mutation 628 (74.3) 338 (75.8) 0.564 
Abbreviations: LV = lymphovascular; HT = Hashimoto’s thyroiditis; CNM = central nodal 528 
metastasis 529 
*even after excluding those with no CLNs harvested (n=138)530 
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Table 3. A comparison of patient clinicopathological features, tumor characteristics and 531 
postoperative stimulated thyroglobulin levels between those with a BRAF mutation (BRAF +ve 532 
group) and without a BRAF mutation (BRAF –ve group) 533 
 BRAF+ve group 
(n=628) 
BRAF-ve group 
(n=217) 
p-value 
Age at operation (years) 45.8 ± 11.9 45.6 ± 11.8 0.802 
Sex 
- Male 
- Female 
 
90 (14.3) 
538 (85.7) 
 
22 (10.1) 
195 (89.9) 
0.116 
Tumor characteristics 
- Tumor size (cm) 
- Microcarcinoma (<1cm)  
- Tumor bilaterality 
- Tumor multifocality 
- Extra-thyroidal extension 
- LV permeation 
- Coexisting HT 
- Occult CNM (pN1a) 
 
0.8 ± 0.4 
460 (73.2) 
135 (21.5) 
225 (35.8) 
383 (61.0) 
53 (8.4) 
217 (34.6) 
235 (37.4) 
 
0.7 ± 0.4 
177 (81.6) 
36 (16.6) 
67 (30.9) 
94 (43.3) 
17 (7.8) 
114 (52.5) 
50 (23.0) 
 
<0.001 
0.045 
0.107 
0.186 
<0.001 
0.780 
<0.001 
<0.001 
Extent of pCND 
- Unilateral 
- Bilateral 
 
483 (76.9) 
145 (23.1) 
 
179 (82.5) 
38 (17.5) 
0.063 
No. of CLNs harvested 
- Unilateral pCND (n=662) 
- Bilateral pCND (n=183) 
6.5 ± 3.6 
6.0 ± 3.2 
8.3 ± 4.3 
6.9 ± 4.3 
6.1 ± 3.0 
10.8 ± 6.7 
0.144 
0.463 
0.105 
No. of metastatic CLNs excised 
- Unilateral pCND (n=662) 
1.0 ± 1.8 
0.8 ± 1.6 
0.7 ± 1.7 
0.5 ± 1.4 
<0.001 
<0.001 
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- Bilateral pCND (n=183) 1.4 ± 2.3 1.5 ± 2.4 0.886 
Central LNR (%) 
- Unilateral pCND (n=662) 
- Bilateral pCND (n=183) 
16.1 ± 26.7 
14.7 ± 25.6 
20.7 ± 29.4 
10.6 ± 24.2 
8.8 ± 22.4 
18.3 ± 30.9 
<0.001 
<0.001 
0.542 
Stage of PTC by TNM 
- Stage I 
- Stage II 
- Stage III 
 
374 (59.6) 
3 (0.5) 
251 (40.0) 
 
155 (71.4) 
1 (0.5) 
61 (28.1) 
0.008 
 
Postsurgical RAI ablation  221 (35.2) 49 (22.6) 0.001 
Pre-ablation 
 - TSH (mIU/L) 
 - sTg level (ug/L)* 
 
99.3 ± 92.2 
2.4 ± 12.7 
 
91.3 ± 59.1 
1.0 ± 1.6 
 
0.539 
0.032 
Post-ablation  
- TSH (mIU/L) 
- sTg level (ug/L)* 
 
119.0 ± 56.1 
0.6 ± 1.8 
 
107.4 ± 40.0 
0.2 ± 0.1 
 
0.356 
0.473 
Continuous variables are expressed as mean ± SD; categorical variables are expressed as number 534 
(percentage) 535 
Abbreviations: PTC = papillary thyroid carcinoma; HT = Hashimoto’s thyroiditis; LV= 536 
lymphovascular; CLN=central lymph node; CNM = central nodal metastasis; pCND = 537 
prophylactic central neck dissection; LNR= lymph node ratio; TNM = 7th edition Tumor, Node 538 
and Metastasis staging system; RAI = radioactive iodine; TSH=thyroid stimulating hormone; 539 
sTg=stimulated thyroglobulin 540 
*after excluding patients with elevated anti-thyroglobulin antibody 541 
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Table 4. A comparison of patient clinicopathologic features and BRAF mutation status between 542 
those with occult central nodal metastases (N1a group) and those without occult central nodal 543 
metastases (N0 group) 544 
 N1a group (n=285) N0 group (n=560) p-value 
Age at operation (years) 45.8 ± 11.9 45.6 ± 11.8 0.285 
Sex (Male : Female) 64 : 221 48 : 512 0.023 
Tumor characteristics 
- Tumor size (cm) 
- Tumor bilaterality 
- Tumor multifocality 
- Extra-thyroidal extension 
- LV permeation 
- Coexisting HT 
 
0.8 ± 0.4 
66 (23.2) 
118 (41.4) 
197 (69.1) 
58 (20.4) 
76 (26.7) 
 
0.7 ± 0.4 
105 (18.8) 
174 (31.1) 
280 (50.0) 
12 (2.1) 
255 (45.5) 
 
0.001 
0.099 
0.003 
<0.001 
<0.001 
<0.001 
BRAF V600E mutation 235 (82.5) 393 (70.2) <0.001 
Abbreviations: HT = Hashimoto’s thyroiditis; LV = lymphovascular 545 
546 
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Table 5. A multivariable analysis of clinicopathological risk factors for occult central lymph 547 
node metastases (N1a)  548 
Covariates ß-coefficient Odds ratio (95% confidence 
interval) 
p-value 
Male sex 0.986 2.681 (1.709 – 4.202) <0.001 
Tumor size 0.987 2.684 (1.802 – 3.997) <0.001 
Tumor multifocality 0.399 1.491 (1.065 – 2.087) 0.020 
Extrathyroidal extension 0.248 1.282 (0.898 – 1.829) 0.171 
Lymphovascular permeation 2.341 10.395 (5.176 – 20.877) <0.001 
Coexisting Hashimoto’s 
thyroiditis 
0.580 0.560 (0.396 – 0.792) 0.001 
BRAF V600E mutation 0.499 1.647 (1.101 – 2.463) 0.015 
 549 
550 
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Table 6a. A comparison of predictability of central nodal metastasis as measured by area under 551 
the receiver operating characteristic curve (AUC) between tumor size and combined preoperative 552 
prediction scores. 553 
 AUC (95% confidence 
interval) 
p-value 
score 1 
vs. 2 
p-value 
score 2 
vs. 3 
p-value 
score 1 
vs. 3 
Prediction score 1 based on tumor 
size only 
0.65 (0.61 – 0.69) 0.33 - - 
Prediction score 2 based on tumor 
size and male sex 
0.68 (0.64 – 0.72) - 0.60 - 
Prediction score 3 based on tumor 
size, male sex and BRAF mutation 
0.69 (0.65 – 0.73) - - 0.13 
Calculated from logistic regression: 554 
Prediction score 1 = -1.716 + 1.288 x (tumor size in cm) 555 
Prediction score 2 = -1.873 + 1.102 (male=1; female=0) + 1.283 x (tumor size in cm) 556 
Prediction score 3 = -2.278 + 1.084 (male=1; female=0) + 1.246 x (tumor size in cm) + 0.569 557 
(BRAF+ve=1; BRAF-ve=0) 558 
The higher the prediction score corresponds to higher risk of occult central nodal metastasis  559 
 560 
Table 6b. A comparison of central nodal metastasis (CNM) rate for each quartile of prediction 561 
score 2 and 3. 562 
 Prediction score 2* CNM (%) Prediction score 3* CNM (%) 
1st quartile 0.00 – 0.51 48/249 (19.3) 0.00 – 0.94 40/228 (17.5) 
2nd quartile 0.52 – 0.89 67/245 (27.3) 0.95 – 1.31 65/233 (27.9) 
3rd quartile 0.90 – 1.41 62/160 (38.8) 1.32 – 1.81 64/177 (36.2) 
4th quartile >1.42 108/191 (56.5) > 1.82 116/207 (56.0) 
Prediction score 2 = -1.873 + 1.102 (male=1; female=0) + 1.283 x (tumor size in cm) 563 
Prediction score 3 = -2.278 + 1.084 (male=1; female=0) + 1.246 x (tumor size in cm) + 0.569 564 
(BRAF+ve=1; BRAF-ve=0) 565 
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*To avoid negative values and facilitate interpretation, +1.74 was added to each prediction score 566 
2 while +2.15 was added to each prediction score 3. This makes no difference to the performance 567 
of the score.568 
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Table 7. Correlation of BRAF mutation status between using fine-needle aspiration (FNA) materials and surgical specimen 569 
Patient 
no. 
Age at 
operation 
(yrs) 
Sex 
(M/F) 
Tumor 
size (cm) 
Occult CNM 
(pN1a) 
BRAF mutation 
On FNA On surgical 
specimen 
Matching between FNA 
and surgical specimen 
1 37 F 0.5 Negative Negative Negative Matched 
2 46 F 1.0 Negative Negative Negative Matched 
3 39 F 0.6 Positive Positive Positive Matched 
4 46 F 0.5 Negative Positive Positive Matched 
5 50 F 0.9 Negative Positive Positive Matched 
6 73 F 0.6 Negative Negative Negative Matched 
7 54 F 0.9 Positive Negative Negative Matched 
8 68 F 0.4 Negative Positive Negative Mismatched 
9 31 F 1.2 Positive Positive Positive Matched 
10 50 M 0.5 Negative Positive Positive Matched 
11 39 F 0.4 Negative Negative Negative Matched 
12 55 F 0.6 Negative Positive Positive Matched 
13 57 F 0.3 Negative Positive Positive Matched 
14 63 F 0.3 Negative Negative Negative Matched 
15 30 F 0.5 Positive Positive Positive Matched 
16 34 F 0.6 Positive Positive Negative Mismatched 
17 55 F 0.3 Negative Positive Positive Matched 
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18 44 F 0.3 Negative Negative Negative Matched 
19 50 F 2.0 Positive Positive Positive Matched 
 570 
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Tables 8A. A 2x2 table between BRAF mutation and central nodal metastasis (CNM) 571 
 572 
 CNM+ve CNM-ve Total 
BRAF+ve 235 393 628 
BRAF-ve 50 167 217 
Total 285 560 845 
Based on these data, the sensitivity, specificity, PPV and NPV of BRAF were 82.5%, 29.8%, 573 
37.4% and 77.0%, respectively. 574 
 575 
Table 8B. A 2x2 table between BRAF mutation and central nodal metastasis (CNM) when the 576 
BRAF prevalence was reduced to 40%. 577 
 578 
 CNM+ve CNM-ve Total 
BRAF+ve 126 212 338 
BRAF-ve 117 390 507 
Total 243 602 845 
Based on these data, the sensitivity, specificity, PPV and NPV of BRAF became 51.9%, 64.8%, 579 
37.3% and 76.9%, respectively. 580 
